Xenon Pharmaceuticals Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $XENE in the last 7 days.
Insiders at Oracle (ORCL) and Xenon Pharmaceuticals (XENE) made significant stock purchases, indicating confidence. ORCL reported strong Q1 earnings with 30% YoY revenue growth, driven by cloud services. XENE submitted an NDA for its epilepsy drug but paused trials for depression treatments. Analysts rate both stocks as Strong Buys with over 60% upside potential.
Xenon Pharmaceuticals' President Ian Mortimer bought US$1.1m worth of stock at US$37.38 per share, increasing his holding by 88%. This is the largest insider purchase in the past year, with insiders buying more shares than they sold. Insiders own 0.1% of the company, worth US$4.4m. The company is currently loss-making.
Xenon Pharmaceuticals (XENE) saw insider buying of $1.68M, with CEO and CFO purchasing shares. The company's lead drug, Azetukalner, is under FDA review for epilepsy. XENE shares rose 5%, their best day in over a month. The company has no revenue and a net loss of $110.7M in Q2, but holds $1.25B in cash.
Recent XENE coverage spans financial news, insider activity and regulation.
In the last 30 days, XENE insiders filed 2 SEC Form 4 transactions — 2 purchases ($1.7M) and no sales. The most active reporter was MORTIMER IAN, PRESIDENT & CEO, with 1 filing.
Insider purchases may offset recent share decline and provide short‑term support.
Insider buying may signal confidence and could create modest buying pressure.
Insider purchases suggest confidence and may drive short-term buying pressure.
Insider purchase suggests confidence and may create modest buying pressure.
Insider purchase suggests confidence from top management, likely supporting short-term price upside.
AlphAI scores every news story that mentions XENE with an AI model for sentiment and relevance, and aggregates insider trades from Xenon Pharmaceuticals Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Insiders at Oracle (ORCL) and Xenon Pharmaceuticals (XENE) made significant stock purchases, indicating confidence. ORCL reported strong Q1 earnings with 30% YoY revenue growth, driven by cloud services. XENE submitted an NDA for its epilepsy drug but paused trials for depression treatments. Analysts rate both stocks as Strong Buys with over 60% upside potential.
3 min readXenon Pharmaceuticals' President Ian Mortimer bought US$1.1m worth of stock at US$37.38 per share, increasing his holding by 88%. This is the largest insider purchase in the past year, with insiders buying more shares than they sold. Insiders own 0.1% of the company, worth US$4.4m. The company is currently loss-making.
2 min readXenon Pharmaceuticals (XENE) saw insider buying of $1.68M, with CEO and CFO purchasing shares. The company's lead drug, Azetukalner, is under FDA review for epilepsy. XENE shares rose 5%, their best day in over a month. The company has no revenue and a net loss of $110.7M in Q2, but holds $1.25B in cash.
1 min readKelly Thomas Patrick (Chief Financial Officer) purchased 15,000 shares of Xenon Pharmaceuticals Inc. (XENE) at $37.32 ($0.56M total) on 2026-09-30.
1 min readXenon Pharmaceuticals' CEO Ian Mortimer bought 30,000 shares at $37.38 each, totaling $1.12M. He now directly owns 49,923 shares and indirectly owns 14,300 via spouse, according to an SEC filing.
1 min readMORTIMER IAN (PRESIDENT & CEO) purchased 30,000 shares of Xenon Pharmaceuticals Inc. (XENE) at $37.38 ($1.12M total) on 2026-09-30.
1 min readXenon Pharmaceuticals (XENE) submitted a New Drug Application for azetukalner in treating focal seizures, while pausing new enrollments in depression studies due to adverse events. The epilepsy program is supported by positive Phase 2b and 3 trial results, with seizure frequency reductions of 53.2% and 34.5% for 25 mg and 15 mg doses, respectively. The psychiatric program's future depends on addressing tolerability issues and upcoming trial results in 2027.
2 min readXenon Pharmaceuticals' stock fell 31% after pausing enrollment in a depression study. The company awaits X-NOVA2 results in early 2027, which may impact its stock. Analysts and safety updates could influence the stock's performance until then.
2 min readGlobal markets are mixed as crude oil prices and bond yields rise. Saudi Arabia aims to restore half of its East-West pipeline capacity, which was shut due to drone strikes. Markets price in a 58% chance of a 25 bp Fed rate hike. Software and cybersecurity stocks fall, while chipmakers and crypto-exposed stocks rise. Netflix drops after a downgrade, and Nucor declines on weaker earnings guidance. Bitcoin gains over 2% after SEC's digital securities plan.
3 min readWall Street closed mixed, with the Nasdaq up 0.4% and the Dow down 0.2%. Investors reacted to the Fed's rate hike and weighed future rate paths. Key earnings reports are upcoming next week. Wells Fargo downgraded Netflix, and Berkshire Hathaway announced Warren Buffett's transition to chairman emeritus.
3 min read
